IMAGE BASED BRACHYTHERAPY FOR CERVICAL CANCER



DR. FIRUZA D.PATEL
PROFESSOR

DEPARTMENT OF RADIOTHERAPY
POSTGRADUATE INSTITUTE OF MEDICAL
EDUCATION & RESEARCH, CHANDIGARH.



- Image <u>guided</u> brachytherapy
 - Technique where imaging is used to guide brachytherapy applicator/source placement.
- Image <u>based</u> brachytherapy
 - Technique where advanced imaging modalities are used to gain information regarding the volumetric dose distribution.



Historically

- Dose prescription & treatment planning have been mainly based on traditional schools using a certain system, including a given technique, loading pattern, & dose rate.
- "Manchester", "Stockholm", "Fletcher/MD Anderson"
- Current practice is to prescribe dose to Point A
- Empiric point, does not reflect dose to tumor, reference is with applicator, is located where dose gradiant is high i.e.about 10%/mm.



- Historically
- Uniform method for reporting ICRU Report 38 (1985)
- Dose be specified in terms of total reference air kerma TRAK
- Reference volume be determined tissue volume
 encomposed by a reference isodose surface, 60 Gy
- Points for dose assessment to bladder & rectum
- Extended to dose-volume histograms DVH for OARs.
- Compare brachytherapy performed in different institutions.
- Applied only minimally, no correlation with primary cervical tumor control.



- Recently
- 3D & 4D image-based brachytherapy treatment planning & dosimetry has been used for Cancer Cervix.
- Prescribed dose is always related to the target while the actual coverage can be evaluated with the use of DVH parameters
- Shape the spatial dose to conform to the target volume
 - Reduce dose to normal tissues & hence reduce the normal tissue toxicity.
 - Escalate dose to the tumor to produce greater rates of local control




- Imaging modalities used
- Ultrasonography
- Fluroscopy
- Computed tomography CT
 - 3D anatomic relationship of applicator & neighbouring structures
 - Difficult to separate cervical tumor from uterus, rectum & bladder & to ascertain where cervix ends & vagina begins
- MRI
- PET



- Imaging modalities used
- MRI Scan
 - Superior soft tissue resolution & is the best imaging modality for visualisation of cervical tumor size, volume & extent
 - Distinction of tumor from normal uterus & cervix
 - Definition of parametrial, & vaginal infiltration of disease
 - Visualise the anatomic relationship between applicator & tumor & adequacy of radiation coverage
 - Doses to rectum & bladder can be assessed
 - Multiplanar scanning capabilities-coronal, sagittal & axial







CT SCAN

MRI SCAN



- Imaging modalities used
- MRI Scan disadvantages
 - MRI compatible applicator made of nonferromagnetic materials. Titanium & zirconium alloy needles.
 - Bony anatomy not differentiated as well as on CT
 - Treatment planning systems use Hounsfield numbers hence they are not able to use MRI scans directly & it is necessary to fuse MRI with CT scans



Imaging modalities used

MRI Scan accuracy

- Tumor volume
- Deep stromal invasion
- Parametrial infiltration
- Lymph node involvement
- Overall Staging

- 93%
- 94%
- 87-94%
- 72-93% similar to CT
- 76-89% better than CT,USG, Clinical




Requirements

- Imaging
- 'Image-able' & artifact free applicator
- Applicator fixation & immobilization
- Treatment planning system
- Compatible communication protocol-DICOM,so that the treatment planning system can interpret the images
- CT & MRI data sets need to be registered to superimpose one set on another
- Contouring tumor & OARs
- Dosimetry & dose-volume parameters for tumor & OARs



Tumor volume assessment


- First based on Clinical Examination
- Appropriate documentation in three dimensions
- Sectional imaging gives information on tumor extension & configuration & its topography






- Target Volume
 - GTV
 - Includes macroscopic tumor extension as detected by clinical examination (visualisation & palpation) & as visualised on MRI
 - Change of GTVs during treatment –
 - At diagnosis GTV_D
 - At brachytherapy GTV_B






















TUMOUR RESPONSE: GOOD

	Volume	Width	Thickness	Height	Distance PSW right	Distance PSW left
Diagnosis: involvement of the right proximal parametrium	88 cm	5 cm	5 cm	7 cm	4 cm	5 cm
Brachytherapy: minimal residual extension into the right parametrium	9 cm'	3 cm	2 cm	3 cm	5 cm	6 cm










The GTV encompasses the macroscopic tumour extension at time of brachytherapy:

high signal intensity mass(es)

(F5E, T2) in cervix/corpus, parametria, vagina, bladder and rectum



Three different target volumes according to cancer cell density



HR: High risk CTV


IR : Intermediate risk CTV


LR: Low risk CTV



- Two CTVs proposed
- High risk CTV (HR CTV)
- Major risk of recurrence because of residual macroscopic tumor
- Intent is to deliver a total dose as high as possible to eradicate all residual macroscopic tumor
- High dose prescribed to this target (80-90+Gy)=dose to point A
- □ Intermediate risk CTV (IR CTV)
- Major risk of recurrence in areas that initially had macroscopic extent of disease with residual microscopic disease at time of BT
- Intent is to deliver dose appropriate to cure microscopic disease in cervix cancer, which corresponds to a dose of 60Gy








The HR-CTV includes


CTV, whole cervix, and presumed
extracervical tumor extension.

Pathologic residual tissue(s) as
defined by palpable indurations
and/or grey zones in parametria,
uterine corpus, vagina or rectum and
bladder are included in HR-CTV.

No safety margin are added








HR-CTV + the initial tumour extension at diagnosis


IR-CTV encompasses HR-CTV
with a safety margin of 5-15 mm.
Amount of safety margin is
chosen according to tumour size
an location, potential tumour
spread, tumour regression and
treatment strategy



- OARs
- Contouring organ wall volumes is difficult
- For organ wall volumes upto 2-3 cm³, organ & organ wall contouring lead to almost identical numerical results this allows for organ contouring only
- If larger organ wall volumes are considered organ wall contouring has to be performed
- When assessing the late effects from brachytherapy, small organ (wall) volumes irradiated to a high dose seems to be of major interest.











- Dose prescription
- The prescribed dose is always related to the target.
- The prescription dose is the planned dose to cover this target as completely as possible.
- Coverage of the target can be improved starting from the standard dose prescription & careful adaptation of the loading pattern & dwell times







Cervix Carcinoma

Alain Gerbaulet, Richard Pötter, Christine Haie-Meder



- Dose prescription
- HR-CTV Dose
 - □ Small tumor 80-85 Gy
 - Large tumor, good response 85-90 Gy
 - Large tumor, poor response 90+ Gy
- IR-CTV ~ 60 Gy
- V(60 Gy_{EQD2}) plays a role for evaluating the IR CTV
- V(85 Gy_{EQD2}) represents more closely the prescription dose to the HR CTV
- For comparison, dose reporting should refer to the prescribed dose to the image-based target & to the traditional system - point A




- Parameters for dosimetric evaluation GTV/CTV
- Prescribed Dose PD
- D100 & D90 minimum dose delivered to 100 & 90% of the volume of interest respectively
- D100 is extremely dependent on target delineation. Due to steep dose gradiants, small spikes in the contour cause large deviations in D100
- D90 is less sensitive to these influences & is therefore considered a more 'stable' parameter
- TRAK
- Point A Dose
- V 100 Volume receiving ≥ 100% of PD
- V150/200 Volume receiving 150%/200% of PD



Dose volume parameters

- Coverage of target volumes can be derived from cumulative DVH analysis
- DVHs for GTV & CTV in I/C brachytherapy have a plateau-100% dose coverage of the volume of interest
- Plateau goes down smoothly indicating decreasing % of dose coverage with increasing dose



Potter, Radiot & Oncol, 78,2006



OARs

- As there is a rapid dose fall-off near the sources, in particular in adjacent small organ (wall) volumes, dose assessment has to refer to one (or more) defined dose points in these limited volumes
- The minimum dose in the most irradiated tissue volume adjacent to the applicator (0.1,1,2,5cm³) is recommended for recording & reporting
- It is assumed that these volumes are contiguous
- This is wrongly called as the 'maximum dose' to a 2cm³ tissue



CLASSICAL MAX DOSE: in 3D no clinical relevant endpoint

FIXED VOLUME: tolerance dose (total dose)"minimum dose to the most exposed tissue"*


0.1 cc: 3D"maximum dose":
ulceration(fistula)

0.1 cm³

2 cm³

6 griv GEC ESTRO Recommendationa(II)
Radiotherapy and Oncology 2006





Potter, Radiot & Oncol, 78,2006



Dose volume constraints

2 cm³ of rectum & sigmoid <75 Gy₃

2 cm³ of bladder < 90 Gy₃

□ High risk CTV & D_{90} greater than the PD $V_{100} > 90\%$




- Radiobiological modelling of doses:
- Standard brachytherapy dose-rate 50cGy/hr
- Calculate the biologically weighted dose for brachytherapy
- Standard external beam radiotherapy is 200cGy/Fr
- Calculate the biologically weighted dose for external beam
- Add both together to get the Total Biologically weighted Dose for tumor & OAR




- Situations requiring combined I/C & I/S
 - Unilateral tumor extension exceeding
 - 3.5 cm at level of ring
 - 2.5 cm at level of pt A
 - 2.2 cm at a distance 3-4cm cranial to ring surface
 - Tumor extension cannot be covered by symmetrical dose distribution of tandem alone without exceeding dose limits for OAR
 - Tumor extension to lower vagina, close to pelvic side wall, posteriorly along ant rectal wall






Potter, Radiot & Oncol, 78,2006







Kirisits, Int J. Rad Oncol Biol Phy 65,2 2006



BALANCE

3-D Image Based Dose volume relations

in OAR: tolerable effects

3-D Image Based Dose volume relations

in HR/IR CTV: control of disease